Print

TRON-Translational Oncology at the University Medical Center of the Johannes Gutenberg University Mainz is biopharmaceutical research organization that pursues new diagnostics and drugs for the treatment of cancer and other severe diseases with high medical need. A focus of TRON is the development of novel platforms for individualized therapies and biomarkers, translating basic research into drug applications. TRON partners with academic institutions, biotech companies and the pharmaceutical industry, executing research with leading-edge technologies and supporting the development of innovative drugs to promote human health.

Spotlight

Vertical Smart Slide 1
Genomics-guided RNA-…
Genomics-guided RNA-based personalized cancer vaccines
Posted 4 days ago

Mainz, Oktober 16, 2014 – Cancer is a disease caused by DNA mutations. 95% of the mutations in a tumor are unique to that single patient and only a small number of mutations are shared between patients. Therefore, a mutation-targeting individualized therapy would benefit each single patient. In the recent edition of the British Journal of Cancer, TRON researchers explain how next-generation sequencing may enable the rapid identification of somatic mutations in individual tumors, paving the way for clinical…

more information

TRON guest lecture O…
TRON guest lecture October 2:  Fighting the Ebola Beast: the Race between a Big Virus and Little Antibodies
Posted 3 weeks ago

Mainz, September 30, 2014 – On October 2, Dr. Javad Aman, will give a guest lecture on the clinical development of a vaccine for Ebola. The 1 p.m. lecture at Building 708, at University Medical Center Mainz takes place as part of the TRON Seminar Series in Translational Oncology.

more information

Mining the genetic i…
Mining the genetic information of cancer cell lines for future therapy development
Posted 1 month ago

Mainz, September 15, 2014 – Cancer cell lines are a tremendous resource for cancer biology and therapy development. In a new research paper in the September issue of OncoImmunology, TRON scientists determined the HLA type and HLA expression of 167 cancer and 10 non-cancer cell lines frequently used for the identification of novel tumor targets and the development of cancer immunotherapies.

more information

Learn about cancer i…
Learn about cancer immunotherapy at Mainz Science Fair
Posted 2 months ago

Mainz, September 03, 2014 – On September 14, TRON researcher Dr. Sebastian Kreiter will explain cancer immunotherapy in a 20-minute presentation aimed at the general public. Dr. Kreiter will speak as part of the Mainz Science Fair in downtown Mainz. On two days, 300 scientists from more than 35 research institutes will present their work, scientific mission, and latest projects with public lectures, hands-on activities and interactive games.

more information

Precise, personal an…
Precise, personal and fast-paced
Posted 3 months ago

Mainz, July 29, 2014 – In an interview in International Innovation magazine, TRON founder and scientific director Ugur Sahin, shares his view on the challenges and opportunities of leading a transdisciplinary, translational, non-profit research organization.

more information

FOCUS magazine featu…
FOCUS magazine features TRON director Ugur Sahin in article on new immunotherapeutic cancer treatments
Posted 4 months ago

Munich, June 27, 2014 – In the 26/14 FOCUS magazine cover article on novel therapies and drugs for the treatment of cancer, TRON founder and scientific director Ugur Sahin talks about the testing of a novel vaccine for the treatment of skin cancer that is being conducted in Mainz.

more information

TRON mentor Prof. Ch…
TRON mentor Prof. Christoph Huber honored as trailblazer of cancer research in Mainz
Posted 4 months ago

Mainz, June 25, 2014 – With a scientific symposium to mark his 70th birthday, the University Medical Center of the Johannes Gutenberg University Mainz has honored Prof. Christoph Huber as a trailblazing cancer clinician and researcher.

more information

Rudern gegen Krebs –…
Rudern gegen Krebs – Rowing challenge to support cancer patients
Posted 5 months ago

Mainz, June 6, 2014 – TRON researchers and staff will again participate in a rowing challenge benefitting “Stiftung Leben mit Krebs”, a national foundation raising funds for people living with cancer.

more information

DNA mutations are tr…
DNA mutations are transcribed to RNA
Posted 5 months ago

Mainz, May 14, 2014 – Therapy selection for cancer patients often depends on the presence or absence of a specific DNA mutation. However, if the mutation is not transcribed RNA, as could be the case for heterozygous mutations, the utility of a DNA-based assay may be compromised. In a just-published report in Nature’s Scientific Reports, TRON researchers have shown that DNA mutations are indeed transcribed to RNA.

more information

TCR transfer into hu…
TCR transfer into human T cells with ecotropic vectors
Posted 6 months ago

Mainz, April 23, 2014 – Efficient retroviral transduction of T cells is crucial for adoptive T-cell transfer in cancer immunotherapy. As now published in the April issue of Gene Therapy, TRON researchers have successfully used transient expression of a receptor protein to make human T cells susceptible for otherwise murine specific retroviruses.

more information

News

Vertical Smart Slide 1
TRON Seminar in Tran…
Posted 4 days ago

Mainz, October 23, 2014 - "Image-Guided Drug Delivery" with Dr. Twan Lammers – Helmholtz Center for Biomedical Engineering, Aachen

mRNA-based therapeut…
Posted 4 weeks ago

Mainz, Germany, September 23, 2014 – A new review article by TRON director Ugur Sahin provides a comprehensive overview of the current state of mRNA-based drug technologies and their applications, and discusses the key challenges and opportunities in developing these into a new class of drugs.

TRON Seminar in Tran…
Posted 1 month ago

Mainz, September 18, 2014 - "Personalization of cancer therapy" with Prof. Hans Lehrach – Max Planck Institute for Molecular Genetics, Berlin

TRON Seminar in Tran…
Posted 2 months ago

The September 4 seminar “New preclinical test systems for an improved analysis of monoclonal antibody function" with Prof. Dr. Ulrich Kalinke Executive Director of TWINCORE, Centre for Experimental and Clinical Infection Research, has been cancelled.

TRON Seminar in Tran…
Posted 2 months ago

Mainz, August 20, 2014 - "Personalized therapies for lung cancer treatment: a paradigm shift in systematical cancer therapy" with Prof. Dr. med. Jürgen Wolf
Center for Integrated Oncology at the University Hospital Cologne and
Prof. Dr. med. Reinhard Büttner
University of Cologne/ Targos GmbH